Carrillo-Torres JH, Peña-Ríos DH

Language: Spanish
References: 38
Page: 458-468
PDF size: 206.16 Kb.

ABSTRACT

Background: Guillain-Barre syndrome is a neurological devastating autoimmune disorder and a neurological emergency with significant morbidity and mortality. In our country there is a lack of epidemiological studies on this disease.
Objective: To describe the clinical features, alterations in laboratory studies, electrophysiological studies and outcome of patients diagnosed with Guillain-Barre hospitalized in the General Hospital of Sonora Dr. Ernesto Ramos Bours.
Patients and method: A retrospective and observational study was made in patients who entered to the General Hospital of Sonora Dr. Ernesto Ramos Bours of Hermosillo, Sonora, with diagnostic suspicion of Guillain-Barre syndrome from January 2007 to December 2011. Also were included patients who entered with diagnostic suspicion different of Guillain-Barre syndrome, but during their study protocol this diagnosis was integrated.
Results: We included 53 patients with a mean age of 41.9 years, 67.9% males. The presentation rate was 10.6 cases per year, 77.4% of these between the months of July to December, predominantly ascending form and axonal varieties. The history of infection was reported in 69.8% of patients, mainly gastrointestinal infections. 30.2% developed cranial nerve involvement. Dissociation albumin - cytology was presented in 32.1% of cases. 69.81% of cases admitted to ICU and 43.4% required mechanical ventilation. Major complications were dysautonomias and pneumonia. 56.6% of patients were treated with plasma exchange. There were 6 deaths.
Conclusions: Guillain-Barre syndrome is a common disease in our environment, with a particular presentation and other than as described in the international literature following a seasonal pattern, predominantly axonal forms and a higher mortality than that reported.

REFERENCES

1. Burns TM. Guillain-Barré syndrome. Semin Neurol 2008; 28:152-167.

2. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquide céphalorachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques des réflexes tendineux. Bull Soc Méd Hóp Paris 1916;40:1462-1470.

3. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-950.

4. Willson HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005;10:94-112.

5. Hughes RAC, Comblath DR. Guillain-Barré syndrome. Lancet 2005; 366: 1653-1666.

6. Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups. Acta Neurol Scand 2001;103:278-287.

7. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-123.

8. Lasky T, Terraciano GJ, Magder L, et al. The Guillain-Barré síndrome and the 1992-1993 y 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-1802.

9. Hughes R. Rees J, Smeeton N, Winter J. Vaccines and Guillain-Barré syndrome. BMJ 1996;312:1475-1476.

10. Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatry 2002;73:348- 349.

11. Greene SK, Rett M, Weintraub ES, et al. Risk of confirmed Guillain-Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project 2009-2010. Am J Epidemiol 2012;175:1100-1109.

12. Wise ME, Viray M, Sejvar JJ, et al. Guillain-Barré syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million americans. Am J Epidemiol 2012;175:1110-1119.

13. Souayah B, Nassar A, Suri MF, Qureshi AI. Guillain-Barré syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007; 25: 5253-5255.

14. Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997;176(suppl 2):S92-S98.

15. Katirji B, Koontz D. Disorders of peripheral nerves. En: Daroff RB, editor. Daroff: BradLey´s neurology in clinical practice. 6th ed. Philadelphia: Elsevier, 2012;1915-2015.

16. McGrogan A, MadLe G, Seaman H, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology 2009;32:150-163.

17. Boglium G. Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy. Acta Neurol Scand 2004;110:100-106.

18. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in paterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology 2003;61:471-474.

19. Nachamkin I, Arzarte Barbosa P, Ung H, et al. Patterns of Guiallin-Barré syndrome in children: results from a Mexican population. Neurology 2007;69:1665-1671.

20. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):S21-S24.

21. Van der Meché FG, van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001;45:133-139.

22. Hadden RDM, Cornblath DR, Hudges RAC, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcomes. Ann Neurol 1998;44:780-788.

23. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2003;60:947-948.

24. Hughes RAC, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130:2245-2257.

25. Shahrizaila N, Yuki Nobuhiro. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action. Expert Opin Pharmacother 2011;12:1551-1560.

26. Sederholm BH. Treatment of acute immune-mediated neuropathies: Guillain-Barré syndrome and clinical variants. Semin Neurol 2010;30:365-372.

27. Hughes RAC, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130:2245-2257.

28. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropiate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298-306.

29. Govoni V, Granieri E. Epidemiology of the Guillain-Barre syndrome. Curr Opin Neurol 2001;14:605-613.

30. Rees JH, Thompson RD, Smeeton NC, et al. Epidemiological study of Guillain-Barre syndrome in South East England. J Nrol Neurosurg Psychiatry 1998;64:74-77.

31. Winer JB. Guillain-Barre syndrome. Mol Pathol 2001;54:381-385.

32. McKhann GM, Cornblath DR, Ho TW, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-597.

33. Roman GC. Tropical neuropathies. In: Hartung HP, ed. Peripheral neuropathies: Part 1. London: Bailliere Tindall, 1995;469-487.

34. Blaser MJ, Olivares A, Taylor DN, et al. Campylobacter serology in patients with Chinese paralytic syndrome. Lancet 1991;338:308.

35. Hardy TA, Blum S, McCombe PA, Redded SW. Guillain-Barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep 2011;11:197-204.

36. Van der Meché FG, van Doorn PA. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995;37(suppl 1):S14-S31.

37. Nishimoto Y, Odaka M, Hirata K, et al. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004;148:200-205.

38. Yang YR, Liu SL, Qin ZY, et al. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome. Cell Mol Neurobiol 2008;28:737-744.